• Ayman Dandal Department of Biochemistry and Microbiology, Faculty of Pharmacy, Aleppo University, Syria
  • Mohammad Yaser Abajy Department of Biochemistry and Microbiology, Faculty of Pharmacy, Aleppo University, Syria
  • Moustafa Alkhalaf Department of Biochemistry and Microbiology, Faculty of Pharmacy, Aleppo University, Syria
  • Ali Ibrahim Department of Biochemistry and Microbiology, Faculty of Pharmacy, Aleppo University, Syria


Objective: Cervical cancer is the second common type of cancer among women worldwide. Infection by certain types of human papillomavirus infection (HPV) such as HPV 16/18 has been considered as the most significant risk factor for the development of cervical cancer. This study was conducted to determine the prevalence HPV 16/18 in women with and without cervical cancer in Aleppo city, Syria.

Methods: Paraffin embedded cervical tissue samples were collected from 113 patients and 40 controls (normal cervix), DNA was extracted and analyzed by PCR for the presence of HPV16/18. Out of 113 cases of cervical carcinoma, 25 cases (22.1%) were carcinoma in situ (CIS), 72 cases (63.7%) were squamous cell carcinomas (SCC) and 16 cases (14.2%) were adenocarcinoma (ADC).

Results: HPV 16 and/or 18 DNA was detected in 84 (74.3%) cases out of 113 of cervical cancers, while it was found in only two of the 40 samples in the control group. At the same time, 9 out of 25 (36%) carcinoma in situ, 61 out of 72(84.72%) squamous cell carcinomas, and 14 out of 16 (87.5%) adenocarcinomas, were positive for HPV 16 and/or 18.

Conclusion: The frequency of infection with HPV 16 and 18 is high among Syrian women and a vaccine against these two types may be effective in about 74% of cervical cancers in Syria.

Keywords: Human papilloma virus (HPV), Cervical cancers, Genotype, HPV vaccination


Download data is not yet available.


1. Kirti, Prabhakar PK. Human papilloma virus associated cervical cancer. Asian J Pharm Clin Res 2016;l 9:14-7.
2. Arbyn M, Castellsague X, de Sanjose S, Bruni L, Saraiya M, Bray F, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011;22:2675–86.
3. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Human Papillomavirus and Related Cancers in World. Summary Report; 2010.
4. Shields TS, Brinton LA, Burk RD, Wang SS, Weinstein SJ, Ziegler RG, et al. A case-control study of risk factors for invasive cervical cancer among US women exposed to oncogenic types of human papillomavirus. Cancer Epidemiol Biomarkers Prev 2004;13:1574-82.
5. De Villiers EM. Crossroads in the classification of papillomaviruses. Virology 2013;445:2-10.
6. Centurioni MG, Puppo A, Merlo DF, Pasciucco G, Cusimano ER, Sirito R, et al. Prevalence of human papillomavirus cervical infection in an Italian asymptomatic population. BMC Infect Dis 2005;5:77.
7. Nurun Nahar B, Shahina T, Munira J, Saif Ullah M, Afzal U. Genotyping of high-risk human papillomavirus (HPV) among cervical precancer and cancer patients. Acta Med Int 2015;2:19-28.
8. Brandstetter T, Böhmer S, Prucker O, Bissé E, zur Hausen A, Alt-Mörbe J, et al. A polymerase based DNA biochip platform for human papillomavirus genotyping. J Virol Methods 2010;163:40–8.
9. Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008;26:1-16.
10. Darnel AD, Wang D, Ghabreau L, Yasmeen Y, Sami S, Akil N, et al. Correlation between the presence of high-risk human papillomaviruses and Id gene expression in syrian women with cervical cancer. Clin Microbiol Infect 2010;16:262-6.
11. Al Moustafa AE, Ghabreau L, Akil N, Alachkar A, Yasmeen A. High-risk HPVs and human carcinomas in the syrian population. Front Oncol 2010;4:68.
12. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. WHO international agency for WHO international agency for research on the cancer monograph working group: a review of human carcinogens-part b: biological agents. Lancet Oncol 2009;10:321–2.
13. Santos C, Munoz N, Klug SJ, Almonte M, Guerrero I, Alvarez M, et al. HPV types and cofactors causing cervical cancer in Peru. Br J Cancer 2001;85:966–71.
14. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;89:12–9.
15. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective International biological study on cervical cancer (IBSCC) study group. J Natl Cancer Inst 1995;87:796-802.
16. Al-Badawi IA, Al-Suwaine A, Al-Aker M, Asaad L, Alaidan A, Tulbah A, et al. Detection and genotyping of human papilloma virus in cervical cancer specimens from Saudi patients. Int J Gynecol Cancer 2011;21:907–10.
17. Hammouda D, Munoz N, Herrero R, Arslan A, Bouhadef A, Oublil M, et al. Cervical carcinoma in algiers, algeria: human papillomavirus and lifestyle risk factors. Int J Cancer 2005;113:483–9.
18. Castellsague X, Klaustermeier J, Carrilho C, Albero G, Sacarlal J, Quint W, et al. Vaccine-related HPV genotypes in women with and without cervical cancer in Mozambique: burden and potential for prevention. Int J Cancer 2008;122:1901-4.
19. Sharifa Ezat WP, Sharifah NA, Sayyidi Hamzi AR, Norin Rahayu S. Prevalence of human papillomavirus genotypes in preinvasive and invasive cervical cancer-a UKM study. Med Health 2010;5:66-76.
20. Elasbali AM, El Din AHS, Abdallah RAH, Ahmed HG. Cervical and oral screening for HR-HPV types 16 and 18 among sudanese women cervical lesions. Infect Agents Cancer 2012;7:17.
21. Odida M, de Sanjosé S, Quint W, Bosch XF, Klaustermeier J, Weiderpass E. Human papillomavirus type distribution in invasive cervical cancer in Uganda. BMC Infectious Diseases 2008;8:85.
22. Jumaah KA, Malla S, Kumar RS. Cloning and characterization of high risk human papilloma virus (HPV) oncogene E6. Asian J Pharm Clin Res 2014;7:61-5.
23. Khodakarami N, Clifford GM, Yavari P, Farzaneh F, Salehpour S, Broutet N, et al. Human papillomavirus infection in women with and without cervical cancer in Tehran, Iran. Int J Cancer 2012;131:156–61.
24. Sowjanya AP, Jain M, Rani Poli U, Padma S, Das M, Shah KV, et al. Prevalence and distribution of high-risk human papilloma virus (HPV) types in invasive squamous cell carcinoma of the cervix and in normal women in Andhra Pradesh, India. BMC Infect Dis 2005;22:116.
25. Rabelo S, Zeferino L, Villa I, Sobrinho J, Amarial R, Magalhaes A. Human papilloma virus prevalence among women with cervical intraepithelial neoplasia III and invasive cervical cancer from Goiania, Brazil. Mem Inst Oswaldo Cruz 2003;198:120-5.
26. Soma M, Kamaraj S. Detection of human papillomavirus in cervical grading by immunohistochemistry and typing of HPV 16 and 18 in high-grades by polymerase chain reaction. J Lab Physicians 2010;2:31–6.
27. Grace Nirmala J, Narendhirakannan RT. Detection and genotyping of high-risk HPV and evaluation of antioxidant status in cervical carcinoma patients in Tamil Nadu State, India–a case control study. Asian Pac J Cancer Prev 2012;12:2689–95.
28. Massad MS, Einstein MH, Huh WK, Katki HA, Kinney WK, Walter K, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Lower Genital Tract Disease 2013;17:S1-S27.
29. Eslami G, Golshani M, Rakhshan M, Fallah F, Goudarzi H, Taghavi A. PCR detection and high-risk typing of human papillomavirus DNA in cervical cancer in iranian women. Cancer Ther 2008;6:361-6.
30. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1157-64.
31. Aldi Y, Trisnawati AN, Putra AE, Djamaan A. Detection of HPV type 45 L2 gene in cervical cancer patients by polymerase chain reaction method. Int J Pharm Pharm Sci 2015;7:129-32.
32. Castellsague X, Diaz M, de Sanjose S, Munoz N, Herrero R, Franceschi S, et al. International agency for research on the cancer multicenter cervical cancer study group. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 2006;98:303–15.
33. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518–27.
34. Saslow D, Solomon D, Lawson H, Killackey M, Kulasingam SL, Cain J, et al. American cancer society, american society for colposcopy and cervical pathology, and american society for clinical pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol 2012;137:516-42.
35. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007;121:621–32.
36. Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003;88:63-73.
37. Tenti P, Romagnoli S, Silini E, Zappatore R, Spinillo A, Giunta P, et al. Human papillomavirus types 16 and 18 infections in infiltrating adenocarcinoma of the cervix: PCR analysis of 138 cases and correlation with histologic type and grade. Am J Clin Pathol 1996;106:52–6.
38. Milde-Langosch K, Schreiber C, Becker G, Loning T, Stegner HE. Human papillomavirus detection in cervical adenocarcinoma by polymerase chain reaction. Hum Pathol 1993;24:590–4.
39. Sangar VC, Ghongane BB, Gupte R, Kesarkar R, Kalyan K, Chowdhary A. Comparison of post-licensure safety surveillance of bivalent and quadrivalent human papilloma virus vaccines in healthy mumbai women. Int J Pharm Pharm Sci 2015;7:437-42.
40. Rajanathan C, Lakshmikanth G, Agastian P. Evaluting the efficacy of aluminum phosphate formulated L2 based human papilloma virus vaccine. Asian J Pharm Clin Res 2015;8:199-201.
301 Views | 643 Downloads
How to Cite
Dandal, A., M. Y. Abajy, M. Alkhalaf, and A. Ibrahim. “PREVALENCE OF HUMAN PAPILLOMA VIRUS TYPES 16 AND 18 AMONG WOMEN WITH CERVICAL CANCER IN ALEPPO, SYRIA”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 9, no. 8, Aug. 2017, pp. 90-93, doi:10.22159/ijpps.2017v9i8.18773.
Original Article(s)